METROPOLIS - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.3
| Stock Code | METROPOLIS | Market Cap | 10,203 Cr. | Current Price | 492 ₹ | High / Low | 566 ₹ |
| Stock P/E | 70.8 | Book Value | 64.0 ₹ | Dividend Yield | 0.20 % | ROCE | 13.4 % |
| ROE | 10.5 % | Face Value | 2.00 ₹ | DMA 50 | 467 ₹ | DMA 200 | 474 ₹ |
| Chg in FII Hold | -1.25 % | Chg in DII Hold | 1.07 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 46.6 Cr. |
| RSI | 63.8 | MACD | 7.38 | Volume | 3,57,477 | Avg Vol 1Wk | 1,52,911 |
| Low price | 397 ₹ | High price | 566 ₹ | PEG Ratio | -5.06 | Debt to equity | 0.11 |
| 52w Index | 56.5 % | Qtr Profit Var | 38.9 % | EPS | 6.66 ₹ | Industry PE | 33.8 |
Analysis: Metropolis Healthcare is trading at 492 ₹, above both its 50 DMA (467 ₹) and 200 DMA (474 ₹), showing short-term strength. RSI at 63.8 and MACD at 7.38 indicate bullish momentum but nearing overbought territory. The stock is well below its 52-week high of 566 ₹, leaving room for recovery. Valuation is stretched with a P/E of 70.8 compared to the industry average of 33.8, while ROCE (13.4%) and ROE (10.5%) remain modest. Quarterly PAT declined (38 Cr vs 46.6 Cr), showing earnings pressure, though EPS at 6.66 ₹ provides a base. The PEG ratio of -5.06 suggests poor valuation relative to growth. Institutional activity is mixed, with FIIs reducing holdings (-1.25%) while DIIs increased (+1.07%). Debt levels are low (0.11), adding financial stability.
Optimal Entry Price: Around 470–480 ₹ (near DMA support zone).
Exit Strategy: If already holding, consider exiting near 560–565 ₹ (recent high resistance zone) or if RSI crosses 70. A stop-loss can be placed around 455 ₹ to manage downside risk.
✅ Positive
- Stock trading above both 50 DMA and 200 DMA, confirming short-term uptrend.
- DII holdings increased (+1.07%), showing domestic institutional support.
- Debt-to-equity ratio at 0.11, indicating low leverage.
- Volume higher than weekly average, showing strong trading interest.
⚠️ Limitation
- High P/E ratio (70.8) compared to industry average.
- PEG ratio at -5.06, suggesting poor valuation relative to growth.
- ROCE (13.4%) and ROE (10.5%) remain modest.
- Quarterly PAT declined (38 Cr vs 46.6 Cr).
📉 Company Negative News
- FII holdings decreased (-1.25%).
- Quarterly profit variation shows decline (-18%).
📈 Company Positive News
- DII holdings increased (+1.07%).
- Stock trading above DMA levels, showing short-term strength.
🏭 Industry
- Industry P/E at 33.8, much lower than Metropolis, highlighting overvaluation.
- Diagnostics sector remains resilient with steady demand but faces competitive pricing pressure.
🔎 Conclusion
Metropolis Healthcare is a moderately suitable candidate for swing trading, supported by technical strength and institutional support. Entry near 470–480 ₹ is optimal, with exit around 560–565 ₹. Risk management is essential due to stretched valuations, declining profits, and reduced FII confidence.